Health Outcomes/Cost of Early vs Delayed ART in Haiti

海地早期 ART 与延迟 ART 的健康结果/成本

基本信息

  • 批准号:
    7110292
  • 负责人:
  • 金额:
    $ 12.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-09-01 至 2008-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): There is debate regarding the optimal time to initiate antiretroviral therapy (ART) in resource-limited settings. The research goal of Dr. Serena Koenig, an infectious disease fellow and associate physician in the Division of Social Medicine and Health Inequalities at Brigham and Women's Hospital, is to determine the optimal time to initiate ART in patients with symptomatic HIV disease in Haiti using a decision modeling approach to incorporate complex trade-offs among clinical benefits, risk of toxicity, and financial cost. She will carry out the proposed health outcomes study in parallel with a randomized control trial that will be conducted by the GHESKIO research center in Port au Prince to compare survival and TB outcomes for early versus delayed treatment of patients with pre-AIDS symptomatic HIV disease. She will be mentored by Drs. Sue Goldie, Warren Johnson, and Jean William Pape. This research plan is composed of three specific aims: 1. To measure quality of life and adherence to ART among patients in the early and delayed treatment groups in the clinical trial, and to conduct an interview study of patients and other members of the Haitian community to compare the values they place on health at different stages of HIV disease. 2. To perform a cost analysis of HIV care in Haiti using clinical trial data and retrospective data collected on patients treated at GHESKIO and elsewhere in Haiti. This analysis will estimate the initial, induced, and averted costs of health-care resources over time for early versus delayed ART. 3. To conduct a cost-effectiveness analysis of early versus delayed ART in Haiti from a societal perspective. Outcome measures will include life expectancy, lifetime total direct medical costs, and costeffectiveness in dollars per quality-adjusted life-year gained and in disability-adjusted life-year gained. Results will be stratified based on the presence or absence of active tuberculosis (TB) infection and sensitivity analyses will examine the impact of adherence rates.
描述(由申请人提供):关于在资源有限的环境中开始抗逆转录病毒治疗(ART)的最佳时间存在争议。 Serena Koenig 博士是布莱根妇女医院社会医学和健康不平等部门的传染病研究员兼副医师,她的研究目标是通过决策建模方法,结合临床获益、毒性风险和财务成本之间的复杂权衡,确定海地有症状 HIV 患者开始 ART 的最佳时间。她将与太子港 GHESKIO 研究中心开展的一项随机对照试验同时进行拟议的健康结果研究,以比较艾滋病前期症状性 HIV 疾病患者的早期治疗与延迟治疗的生存率和结核病结果。她将受到博士的指导。苏·戈尔迪、沃伦·约翰逊和让·威廉·佩普。该研究计划由三个具体目标组成: 1. 衡量临床试验中早期和延迟治疗组患者的生活质量和对 ART 的依从性,并对患者和海地社区其他成员进行访谈研究,比较他们在艾滋病毒疾病不同阶段对健康的价值观。 2. 利用临床试验数据和对在 GHESKIO 和海地其他地方接受治疗的患者收集的回顾性数据,对海地的艾滋病毒护理成本进行分析。该分析将估计早期与延迟 ART 的初始、诱发和避免的医疗资源成本随时间的变化。 3. 从社会角度对海地的早期抗逆转录病毒疗法与延迟抗逆转录病毒疗法进行成本效益分析。结果指标将包括预期寿命、终生总直接医疗费用以及每增加质量调整生命年和增加伤残调整生命年的成本效益(以美元计)。结果将根据是否存在活动性结核病 (TB) 感染进行分层,敏感性分析将检查依从率的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SERENA Patricia KOENIG其他文献

SERENA Patricia KOENIG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SERENA Patricia KOENIG', 18)}}的其他基金

PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
PRESCIENT:一项针对药物敏感结核病的超短疗程贝达喹啉、氯法齐明、吡嗪酰胺和德拉马尼与标准疗法的 IIc 期、开放标签、随机对照试验
  • 批准号:
    10488329
  • 财政年份:
    2022
  • 资助金额:
    $ 12.81万
  • 项目类别:
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
PRESCIENT:一项针对药物敏感结核病的超短疗程贝达喹啉、氯法齐明、吡嗪酰胺和德拉马尼与标准疗法的 IIc 期、开放标签、随机对照试验
  • 批准号:
    10661811
  • 财政年份:
    2022
  • 资助金额:
    $ 12.81万
  • 项目类别:
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care
当日艾滋病毒检测和治疗启动,以提高护理保留率
  • 批准号:
    8623097
  • 财政年份:
    2013
  • 资助金额:
    $ 12.81万
  • 项目类别:
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care
当日艾滋病毒检测和治疗启动,以提高护理保留率
  • 批准号:
    8540744
  • 财政年份:
    2013
  • 资助金额:
    $ 12.81万
  • 项目类别:
Health Outcomes/Cost of Early vs Delayed ART in Haiti
海地早期 ART 与延迟 ART 的健康结果/成本
  • 批准号:
    7286030
  • 财政年份:
    2004
  • 资助金额:
    $ 12.81万
  • 项目类别:
Cost-effectiveness of Early vs. Delayed Antiretroviral Therapy in Haiti
海地早期抗逆转录病毒治疗与延迟抗逆转录病毒治疗的成本效益
  • 批准号:
    7761257
  • 财政年份:
    2004
  • 资助金额:
    $ 12.81万
  • 项目类别:
Health Outcomes/Cost of Early vs Delayed ART in Haiti
海地早期 ART 与延迟 ART 的健康结果/成本
  • 批准号:
    6863052
  • 财政年份:
    2004
  • 资助金额:
    $ 12.81万
  • 项目类别:
Cost-effectiveness of Early vs. Delayed Antiretroviral Therapy in Haiti
海地早期抗逆转录病毒治疗与延迟抗逆转录病毒治疗的成本效益
  • 批准号:
    7558017
  • 财政年份:
    2004
  • 资助金额:
    $ 12.81万
  • 项目类别:
Cost-effectiveness of Early vs. Delayed Antiretroviral Therapy in Haiti
海地早期抗逆转录病毒治疗与延迟抗逆转录病毒治疗的成本效益
  • 批准号:
    8018138
  • 财政年份:
    2004
  • 资助金额:
    $ 12.81万
  • 项目类别:
Health Outcomes/Cost of Early vs Delayed ART in Haiti
海地早期 ART 与延迟 ART 的健康结果/成本
  • 批准号:
    6952012
  • 财政年份:
    2004
  • 资助金额:
    $ 12.81万
  • 项目类别:

相似海外基金

Re-igniting Windrush folk song and stories to improve African-Caribbean mental health disparities
重新点燃 Windrush 民歌和故事,改善非洲和加勒比地区的心理健康差异
  • 批准号:
    AH/X012387/1
  • 财政年份:
    2023
  • 资助金额:
    $ 12.81万
  • 项目类别:
    Research Grant
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 12.81万
  • 项目类别:
    Fellowship Programs
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    493049
  • 财政年份:
    2023
  • 资助金额:
    $ 12.81万
  • 项目类别:
Optimizing the vaginal microbiome In African, Caribbean and other Black women from Toronto, Canada: defining clinical endpoints and community priorities
优化来自加拿大多伦多的非洲、加勒比和其他黑人女性的阴道微生物组:确定临床终点和社区优先事项
  • 批准号:
    494152
  • 财政年份:
    2023
  • 资助金额:
    $ 12.81万
  • 项目类别:
    Operating Grants
Strengthening community capacity for HIV prevention and care among African Caribbean and Black (ACB) women in Ontario: An interdisciplinary community-based participatory research initiative
加强安大略省非洲加勒比和黑人 (ACB) 妇女艾滋病毒预防和护理的社区能力:一项基于社区的跨学科参与性研究计划
  • 批准号:
    463487
  • 财政年份:
    2022
  • 资助金额:
    $ 12.81万
  • 项目类别:
    Operating Grants
A-AIDS-2022-01037 and titled "Because she cares: Using spoken word films as a performance-educational tool to catalyze discussion around Canadian AASO employment as (un)caring work for African, Caribbean and Black women living with HIV”
A-AIDS-2022-01037,标题为“因为她关心:使用口语电影作为表演教育工具来促进围绕加拿大 AASO 就业的讨论,作为对感染艾滋病毒的非洲、加勒比和黑人妇女的(非)关怀工作”
  • 批准号:
    467867
  • 财政年份:
    2022
  • 资助金额:
    $ 12.81万
  • 项目类别:
Implementing Client-Centered Care Coordination to Enhance Equity in the HIV Prevention Impact of PrEP among African, Caribbean and Black Communities in Toronto: A Community-Academic Partnership
实施以客户为中心的护理协调,以增强多伦多非洲、加勒比和黑人社区中 PrEP 艾滋病毒预防影响的公平性:社区学术伙伴关系
  • 批准号:
    467754
  • 财政年份:
    2022
  • 资助金额:
    $ 12.81万
  • 项目类别:
    Operating Grants
Exploring the Lived Experiences of African, Caribbean and Black Digital Health Users and their Perceptions of Trust: A Qualitative Study
探索非洲、加勒比和黑人数字健康用户的生活经历及其对信任的看法:一项定性研究
  • 批准号:
    486192
  • 财政年份:
    2022
  • 资助金额:
    $ 12.81万
  • 项目类别:
    Studentship Programs
Acceptability of HIV/STBBI Dried Blood Spot Testing Among African, Caribbean, and Black Communities in Manitoba
马尼托巴省非洲、加勒比和黑人社区对 HIV/STBBI 干血斑检测的接受度
  • 批准号:
    486104
  • 财政年份:
    2022
  • 资助金额:
    $ 12.81万
  • 项目类别:
    Studentship Programs
Strengthening the capacity of healthcare providers to reduce the impact of COVID-19 on African, Caribbean, and Black communities in Ontario
加强医疗保健提供者的能力,减少 COVID-19 对安大略省非洲、加勒比和黑人社区的影响
  • 批准号:
    459182
  • 财政年份:
    2021
  • 资助金额:
    $ 12.81万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了